HOME >> BIOLOGY >> NEWS
JCI table of contents: Oct. 5, 2006

at is characterized by the presence of fluid-filled blisters on the skin. Individuals with BP have large amounts of antibodies that recognize two of the individual's own proteins (BP180 and BP230), but exactly how these antibodies cause disease has not be determined. Now, in a study using a mouse model of BP, which appears online on October 5 in advance of publication in the November print issue of the Journal of Clinical Investigation, researchers from the University of North Carolina, have shown that these antibodies activate an immune system pathway known as the classical complement pathway.

Transfer of antibodies specific for mouse BP180 to other mice induces the formation of blisters similar to those seen in individuals with BP. However, Zhi Liu and colleagues found that these antibodies do not cause disease in mice lacking C4 (a crucial component of the classical complement pathway). In the absence of activation of the classical complement pathway, immune cells known as mast cells were not activated and neutrophils (another immune cell type) were not recruited to the skin. This study identifies a mechanism by which self-reactive antibodies can cause blister formation in mice, and might lead to new treatments for individuals with BP and other autoimmune blistering diseases, such as herpes gestationis -- which is a nonviral disease of pregnancy.

TITLE: Role of different pathways of the complement cascade in experimental bullous pemphigoid

AUTHOR CONTACT:

Zhi Liu
University of North Carolina, Chapel Hill, North Carolina, USA.
Phone: (919) 966-0788; Fax: (919) 966-3898; E-mail: zhiliu@med.unc.edu.

View the PDF of this article at: https://www.the-jci.org/article.php?id=17891


NEUROBIOLOGY: Too many copies of Rai1 spoil development

Disorders that result from duplication or deletion of l
'"/>

Contact: Karen Honey
press_releases@the-jci.org
212-342-9006
Journal of Clinical Investigation
5-Oct-2006


Page: 1 2 3 4

Related biology news :

1. Antioxidant overload may underlie a heritable human disease
2. JCI table of contents: Aug. 9, 2007
3. JCI table of contents: August 1, 2007
4. US Department of Defense awards $1.6 million for implantable biochip research
5. More fish oil, less vegetable oil, better for your health
6. JCI table of contents -- July 26, 2007
7. JCI table of contents: July 19, 2007
8. JCI table of contents: July 12, 2007
9. JCI table of contents: June 21, 2007
10. JCI table of contents: June 14, 2007
11. Food safety begins as vegetables grow

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: JCI table contents Oct

(Date:7/23/2014)... Chrysomya megacephala is commonly found in dead bodies ... time of death, referred to as the post mortem ... C. megacephala from Tamil Nadu is provided for ... characterization through generation of DNA barcoding. This study, significant ... Biodiversity Data Journal . , Chrysomya megacephala ...
(Date:7/23/2014)... New Rochelle, NY -- The potential for clinical ... for transplant-based therapeutic strategies has previously been hindered ... the development of tumors. The ability to use ... for the treatment of heart disease, specifically acute ... Stem Cells and Development , a peer-reviewed ...
(Date:7/23/2014)... MINNETONKA, Minn. , July 23, 2014 /PRNewswire/ ... technology company specializing in clinical study management systems, ... West , a proven life sciences industry executive ... named Chief Operating Officer (COO).  Clareece will be ... and sales growth, operational efficiency and quality product/service ...
Breaking Biology News(10 mins):Dead body feeding larvae useful in forensic investigations 2MedNet Appoints Clareece West As Chief Operating Officer 2
(Date:7/23/2014)... July 23, 2014 ... of Trendlines Agtech , announced it has ... Israel,s leading agricultural thermoplastics applications companies. ... Valentis,s technology combines nanocrystalline cellulose (NCC), a biodegradable, ... additional nanoparticles to produce highly improved polymeric films. ...
(Date:7/23/2014)... regulated information -- UCB today announced an important advance ... topline results from the latest Phase 3 study ... evaluate the efficacy and safety of brivaracetam ... to placebo, as adjunctive treatment in adult focal ... despite treatment with one or two concomitant antiepileptic ...
(Date:7/23/2014)... 2014  Sofinnova Ventures, a Menlo Park ... of Sofinnova Venture Partners IX, L.P. at the hard ... initial fund target of $425 million. Sofinnova ... Consistent with recent funds, SVP IX will provide capital ... along with select investments in earlier stage opportunities. Investments ...
(Date:7/23/2014)... 2014 OncLive® is pleased to ... joined its Strategic Alliance Partnership program. , ... UNC Lineberger will have the opportunity to work ... its cutting-edge research initiatives, community-directed cancer prevention programs, ... work with OncLive to educate their peers by ...
Breaking Biology Technology:Valentis Nanotech Signs MOU to Integrate Technology in Thermoplastics Production 2Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 2Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 3Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 4Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 5Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 6Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 7Sofinnova Raises $500 Million Biotech Venture Fund 2OncLive Expands Its Strategic Alliance Partnership Program With the Addition of UNC Lineberger Comprehensive Cancer Center 2OncLive Expands Its Strategic Alliance Partnership Program With the Addition of UNC Lineberger Comprehensive Cancer Center 3
Cached News: